Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit model

Vaccine

Volumn 27, Issue 40, 2009, Pages 5496-5504

  Garza, Nicole L ^a   Hatkin, Josh M ^a   Livingston, Virginia ^a   Nichols, Donald K ^a   Chaplin, Paul J ^b   Volkmann, Ariane ^b   Fisher, Diana ^a   Nalca, Aysegul ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Bavarian Nordic GmbH   (Germany)

Author keywords

Aerosol; IMVAMUNE ; MVA; Rabbitpox virus; Smallpox vaccine

Indexed keywords

MVA BN; PHOSPHATE BUFFERED SALINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; LETHAL DOSE; LOW DRUG DOSE; MALE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; NEUTRALIZATION TESTS; PLAQUE ASSAY; RABBITS; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA; VACCINIA VIRUS; VIRAL LOAD;

EID: 68349158808     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.105     Document Type: Article

References (25)

1. Greene H.S.N. A pandemic of rabbit-pox. Proc Soc Exp Biol Med 30 (1933) 892-894
2. Fenner F. Rabbitpox virus. In: Osterhaus A.D. (Ed). Virus infections of rodents and lagomorphs (1994), Elsevier, New York 51-57
3. Adams M.M., Rice A.D., and Moyer R.W. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 81 (2007) 11084-11095
4. Nalca A., Hatkin J.M., Garza N.L., Nichols D.K., Hurby D.E., and Jordan R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79 (2008) 121-127
5. Henderson D.A. Countering the posteradication threat of smallpox and polio. Clin Infect Dis 34 (2002) 79-83
6. Mayr A., Hochstein-Mintzel V., and Stickl H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA (passage history, properties, and applicability of the attenuated vaccinia virus strain MVA). Infection 3 (1975) 6-14
7. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 (1991) 1031-1038
8. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 88 (2007) 3249-3259
9. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. MVA-stufenimpfung gegen pocken. Kleinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA (MVA vaccination against smallpox:clinical tests with an attenuated live vaccinia virus strain (MVA)). Dtsch Med Wschr 99 (1974) 2386-2392
10. Kennedy J.S., and Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 8 (2009) 13-24
11. Jones T. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection. Curr Opin Mol Ther 10 (2008) 407-417
12. 21 CFR Parts 314 and 601. New Drug and Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible; 2002. Food and Drug Administration, HHS.
13. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Heweston J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 (2001) 4768-4773
14. Roy C.J., and Pitt L.M.L. Infectious disease aerobiology: aerosol challenge methods. In: Swearengen J.L. (Ed). Biodefense: research methodology and animal models (2006), CRC Press, Boca Raton, FL 61-76
15. Kulesh D.A., Baker R.O., Loveless B.M., Norwood D., Zwiers S.H., Mucker E., et al. Smallpox and pan-orthopox virus detection by real-time 3′-minor groove binder TaqMan assays on the Roche lightcycler and the Cepheid smart cycler platforms. J Clin Microbiol 42 (2004) 601-609
16. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 (2006) 2065-2070
17. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 1803 (2003) 1-14
18. McClain D.J., Harrison S., Yeager C.L., Cruz J., Ennis F.A., Gibbs P., et al. Immunologic responses to vaccinia vaccines administrated by different parenteral routes. J Infect Dis 175 (1997) 756-763
19. Samuelsson C., Hausmann J., Lauterbach H., Schmidt M., Akira S., Wagner H., et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 118 (2008) 1776-1784
20. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79 (2005) 7845-7851
21. Frey S.E., Newman F.K., Kennedy J.S., Sobek V., Ennis F.A., Hill H., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax® challenge. Vaccine 25 (2007) 8562-8573
22. Davies D.H., Wyatt L.S., Newman F.K., Earl P.L., Chun S., Hernandez J.E., et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J Virol 82 (2008) 652-663
23. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 (2005) 164-175
24. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 (2004) 182-185
25. Wyatt L.S., Earl P.L., Eller L.A., and Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. PNAS March (101) (2004) 4590-4595